{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:15:17Z","timestamp":1781702117140,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurocirug\u00eda"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.neucir.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T06:45:44Z","timestamp":1506667544000},"page":"276-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Factores pron\u00f3sticos y predictivos en gliomas de alto grado. Experiencia en nuestro centro"],"prefix":"10.1016","volume":"28","author":[{"given":"Diana","family":"Alonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Matallanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Riveros-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maripaz","family":"P\u00e9rez-Payo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neucir.2017.07.005_bib0085","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol (Berl)."},{"key":"10.1016\/j.neucir.2017.07.005_bib0090","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.neucir.2017.07.005_bib0095","series-title":"Brain tumors: An enciclopedic approach","first-page":"31","article-title":"Classification and pathogenesis of brain tumors","author":"Gonzales","year":"1995"},{"key":"10.1016\/j.neucir.2017.07.005_bib0100","doi-asserted-by":"crossref","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol. 2007;114:97-109. doi:10.1007\/s00401-007-0243-4.","DOI":"10.1007\/s00401-007-0243-4"},{"key":"10.1016\/j.neucir.2017.07.005_bib0105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0360-3016(98)00159-X","article-title":"Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma","volume":"41","author":"Laperriere","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.neucir.2017.07.005_bib0110","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2003.10.035","volume":"21","author":"Grossman","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.neucir.2017.07.005_bib0115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.arcmed.2013.04.004","article-title":"MGMT Promoter methylation and glioblastoma prognosis: A systematic review and meta-analysis","volume":"44","author":"Chen","year":"2013","journal-title":"Arch Med Res."},{"key":"10.1016\/j.neucir.2017.07.005_bib0120","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefict from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.neucir.2017.07.005_bib0125","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1200\/JCO.2009.23.6497","article-title":"NOA-04 randomized phase iii trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine and vincristine or temozolomida","volume":"27","author":"Wick","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.neucir.2017.07.005_bib0130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.arcmed.2013.04.004","article-title":"MGMT pomoter methylation and glioblastoma prognosis: A systematic review and meta-analysis","volume":"44","author":"Chen","year":"2013","journal-title":"Arch Med Res."},{"key":"10.1016\/j.neucir.2017.07.005_bib0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1748-717X-6-115","article-title":"Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?","volume":"6","author":"Combs","year":"2011","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.neucir.2017.07.005_bib0140","doi-asserted-by":"crossref","first-page":"e58206","DOI":"10.1371\/journal.pone.0058206","article-title":"Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations","volume":"8","author":"Ramalho-Carvalho","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.neucir.2017.07.005_bib0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1440-1789.2008.00998.x","article-title":"Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin","volume":"29","author":"Park","year":"2009","journal-title":"Neuropathology."},{"key":"10.1016\/j.neucir.2017.07.005_bib0150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"National Cancer Institute of Canada Clinical Trials Group, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"Suppl 3","key":"10.1016\/j.neucir.2017.07.005_bib0155","doi-asserted-by":"crossref","first-page":"iii93","DOI":"10.1093\/annonc\/mdu050","article-title":"High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Stupp","year":"2014","journal-title":"Ann Oncol."},{"key":"10.1016\/j.neucir.2017.07.005_bib0160","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamaneurol.2014.3739","article-title":"Treatment of elderly patients with glioblastoma: A systematic evidence-based analysis","volume":"72","author":"Zarnett","year":"2015","journal-title":"JAMA Neurol."}],"container-title":["Neurocirug\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113014731730088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113014731730088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T02:38:46Z","timestamp":1535337526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S113014731730088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S113014731730088X"],"URL":"https:\/\/doi.org\/10.1016\/j.neucir.2017.07.005","relation":{},"ISSN":["1130-1473"],"issn-type":[{"value":"1130-1473","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factores pron\u00f3sticos y predictivos en gliomas de alto grado. Experiencia en nuestro centro","name":"articletitle","label":"Article Title"},{"value":"Neurocirug\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neucir.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Sociedad Espa\u00f1ola de Neurocirug\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}